Outlook Therapeutics, Inc. OTLK
Set alert
At close · Nov 2
After hours · Nov 2, 6:58 PM ET
- YTD
- -70.30%
- 1 year
- -62.76%
- Open
- 0.4691
- Prev close
- 0.4681
- Mkt cap
- 114.23M
- Vol
- 2.28M
- Avg vol
- 10.20M
- EPS
- -0.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.4457
- High
- 0.4817
- Forward P/E
- -0.55
- Beta
- 0.63
- Short ratio
- 1.26
- Inst. own
- 35.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 27, 2024
- 50-d avg
- 4.24
- 200-d avg
- 6.73
- 1y target
- 24.80
5D chart
Signals (109)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 9:40 AM | 17 hours ago |
| SMA: Bullish | Nov 2, 9:35 AM | 17 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 17 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 17 hours ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:20 PM | 3 days ago |
| RSI: Oversold | Oct 30, 1:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:20 AM | 3 days ago |
Newest 20 of 109.
News
2 weeks ago defenseworld.net
Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
3 weeks ago globenewswire.com
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) Veteran retina commercial leader, who has helped…
3 weeks ago globenewswire.com
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company's path forward following the FDA approval of LYTENAVA™
-
1 month ago benzinga.com
Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal…
1 month ago globenewswire.com
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE)…
1 month ago businesswire.com
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced…
1 month ago defenseworld.net
Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)
Synlogic (NASDAQ: SYBX - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
1 month ago globenewswire.com
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst
-
1 month ago benzinga.com
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
1 month ago globenewswire.com
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Access the segment here
2 months ago globenewswire.com
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise…
2 months ago globenewswire.com
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Video webcast now available here
2 months ago zacks.com
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
2 months ago benzinga.com
5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In
U.S. stocks fell, but S&P 500 gained 0.4% for 3rd week. Wall Street analysts make new stock picks daily, Benzinga's data can help make better trades.
2 months ago defenseworld.net
Oncobiologics Q3 Earnings Call Highlights
Oncobiologics (NASDAQ: OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic…
2 months ago defenseworld.net
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies…
-
2 months ago benzinga.com
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.
2 months ago seekingalpha.com
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
2 months ago marketbeat.com
Oncobiologics Q3 Earnings Call Highlights
Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation…
2 months ago benzinga.com
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga…
2 months ago zacks.com
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Outlook Therapeutics, Inc. (OTLK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.44 per share a year ago.
-
2 months ago benzinga.com
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the…
2 months ago globenewswire.com
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
2 months ago benzinga.com
S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone
CNN Fear & Greed index showed improved market sentiment, with S&P 500 hitting a new record high after PPI data release. Nasdaq up 0.81%.
2 months ago benzinga.com
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.
2 months ago benzinga.com
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…
2 months ago globenewswire.com
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
-
2 months ago benzinga.com
Outlook Therapeutics Launches Underwritten Public Offering Of Common Stock And Warrants To Fund LYTENAVA Launch; No Financial Terms Disclosed
Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for…
2 months ago globenewswire.com
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved…
3 months ago benzinga.com
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection
The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
3 months ago benzinga.com
This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analyst ratings page before buying.
-
3 months ago benzinga.com
BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.
-
3 months ago benzinga.com
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and…
4 months ago benzinga.com
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
4 months ago benzinga.com
Outlook Therapeutics Says FDA Accepts Resubmitted BLA For ONS-5010/LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration; PDUFA Target Action Date July 29
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
4 months ago benzinga.com
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.
-
4 months ago benzinga.com
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session